William Greenman - Cerus CEO and President and Director
| CERS Stock | USD 1.82 0.06 3.41% |
CEO
Mr. William M. Greenman is President, Chief Executive Officer, Director of Cerus Corporationrationration. Mr. Greenman has served as our President and Chief Executive Officer and a member of our Board since April 2011. Mr. Greenman served as our Senior Vice President, Business Development and Marketing from August 2008 until April 2011 and was named our Chief Business Officer in April 2010. Mr. Greenman served as our President, Cerus Europe, from 2006 until August 2008. From 1999 to 2006, Mr. Greenman served as our Vice President, Business Development after returning to Cerus after a brief time in the VC business. Prior to joining us in 1995 as Director of Business Development, Mr. Greenman worked in various marketing and business development positions in Baxters Biotech Division from 1991 to 1995. Mr. Greenman has served on the board of directors of Aduro Biotech, Inc., a public clinicalstage immunotherapy company, since June 2010 since 2011.
| Age | 57 |
| Tenure | 13 years |
| Address | 1220 Concord Avenue, Concord, CA, United States, 94520 |
| Phone | 925 288 6000 |
| Web | https://www.cerus.com |
Cerus Management Efficiency
The company has return on total asset (ROA) of (0.0373) % which means that it has lost $0.0373 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3831) %, meaning that it created substantial loss on money invested by shareholders. Cerus' management efficiency ratios could be used to measure how well Cerus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.24 in 2024. At this time, Cerus' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 34.3 M in 2024, whereas Total Current Assets are likely to drop slightly above 99.5 M in 2024.Similar Executives
| Showing other executives | CEO Age | ||
| Joshua Levine | Accuray Incorporated | 66 | |
| Maher Masoud | MaxCyte | 49 | |
| Joel Becker | Neuropace | 56 | |
| Steven Williamson | Pulmonx Corp | 51 | |
| Taylor Harris | Cutera Inc | 48 | |
| Robert Claypoole | Bioventus | 52 | |
| Kevin Hykes | CVRx Inc | 58 | |
| Massimo Calafiore | Orthofix Medical | 52 | |
| Gary Maharaj | SurModics | 61 | |
| Juan Quiros | Establishment Labs Holdings | 51 | |
| David Mowry | Cutera Inc | 62 | |
| Robert Spignesi | Rapid Micro Biosystems | 54 | |
| Burkhard Prause | Bruker | 57 | |
| Nadim Yared | CVRx Inc | 56 | |
| Suzanne MBA | Accuray Incorporated | 61 | |
| Joseph Dziedzic | Integer Holdings Corp | 56 | |
| Glendon French | Pulmonx Corp | 62 | |
| Mark Throdahl | Orthopediatrics Corp | 73 | |
| Karen Zaderej | Axogen Inc | 62 | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.0373 |
Cerus Leadership Team
Elected by the shareholders, the Cerus' board of directors comprises two types of representatives: Cerus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cerus. The board's role is to monitor Cerus' management team and ensure that shareholders' interests are well served. Cerus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cerus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Notarianni, Director Relations | ||
| Richard Benjamin, Chief Medical Officer | ||
| Kevin Green, CFO and VP of Fin. | ||
| William Greenman, CEO and President and Director | ||
| Carol Moore, Sr. VP of Regulatory Affairs, Quality and Clinical | ||
| Lainie Corten, Sr. Director, Global Marketing & Investor Relations | ||
| Vivek Jayaraman, Chief Commercial Officer | ||
| Chrystal Jensen, Chief Counsel | ||
| Laurence MD, CoFounder Officer | ||
| Jessica Hanover, Vice Affairs | ||
| Chrystal Menard, Chief Legal Officer | ||
| Lori Roll, VP Secretary | ||
| Kevin CPA, VP CFO | ||
| Dr MBChB, Chief Officer | ||
| Laurence Corash, Senior Vice President Chief Medical and Chief Scientific Officer, Director | ||
| Alicia Goodman, Chief Officer | ||
| Chrystal JD, Chief Counsel | ||
| Nina Mufti, Senior Development |
Cerus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cerus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.0373 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 349.19 M | ||||
| Shares Outstanding | 185.72 M | ||||
| Shares Owned By Insiders | 3.27 % | ||||
| Shares Owned By Institutions | 79.26 % | ||||
| Number Of Shares Shorted | 7.93 M | ||||
| Price To Earning | (4.70) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cerus Stock Analysis
When running Cerus' price analysis, check to measure Cerus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerus is operating at the current time. Most of Cerus' value examination focuses on studying past and present price action to predict the probability of Cerus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerus' price. Additionally, you may evaluate how the addition of Cerus to your portfolios can decrease your overall portfolio volatility.